Company Focus
Galderma
Latest Galderma News
Biotechnology
The US Food and Drug Administration (FDA) has approved Galderma’s Nemluvio (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. 14 August 2024
Dermatology News
Insights
Company Spotlight
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.
Latest News & Features of interest to Galderma
Pharmaceutical
Privately-held Danish company MC2 Therapeutics today announced an agreement under which a Huadong Medicine unit has been granted exclusive rights in Greater China to develop and commercialize MC2’s drug, Wynzora Cream for the treatment of plaque psoriasis. 31 August 2023
Pharmaceutical
Today, the US Centers for Medicare & Medicaid Services (CMS) has for the first time selected 10 drugs for negotiation. Seniors paid $3.4 billion in out-of-pocket costs for these drugs in 2022, the CMS stated. 29 August 2023
Biosimilars
US pharmacy benefit manager (PBM) CVS Health today revealed it has set up a wholly-owned subsidiary, named Cordavis. 24 August 2023
Biotechnology
Japanese mid-size drugmaker Kyowa Kirin says it has received approval from the Ministry of Health, Labor and Welfare (MHLW) for partial change of approved indication of Lumicef (brodalumab [genetical recombination]) for the treatment of palmoplantar pustulosis (PPP) that respond inadequately to existing therapies. 24 August 2023
Biotechnology
Bristol Myers Squibb has been granted a new European approval for Opdivo (nivolumab) as a monotherapy in skin cancer. 23 August 2023
Pharmaceutical
US rare and orphan dermatologic diseases firm Timber Pharmaceuticals saw it shares almost double to $2.79 this morning, on the news of a takeover bid. 21 August 2023
Pharmaceutical
The European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for Danish dermatology specialist LEO Pharma’s delgocitinib cream. 18 August 2023
Biotechnology
Positive data for a new kind of medicine, a BTK inhibitor developed by Novartis, could pave the way to improved treatment options for people with chronic spontaneous urticaria. 9 August 2023
Biosimilars
German companies Fresenius Kabi and Formycon have reached a settlement with US healthcare giant Johnson & Johnson for the USA, concerning FYB202, a proposed biosimilar to Stelara (ustekinumab). 8 August 2023
Biotechnology
Nektar Therapeutics’ shares closed up a massive 82.6% at $0.98 yesterday, after it revealed announced that efficacy data previously generated by former partner Eli Lilly for Rezpeg (rezpegaldesleukin) that were presented at the September 2022 EADV Congress were incorrectly calculated by Lilly. 8 August 2023
Latest In Brief for Galderma
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Latest Dermatology Ones To Watch News
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
18 September 2024
13 August 2024
24 July 2024
17 May 2024
Dermatology Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze